Related Experiment Video

Updated: Apr 16, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors

Shanthi Kanthala1, Sandeep Pallerla, Seetharama Jois

  • 1Basic Pharmaceutical Sciences, School of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA.

Future Oncology (London, England)
|March 12, 2015
PubMed

Insights

High expression of epidermal growth factor receptors (EGFRs) occurs in many cancers. Understanding EGFR mutations and resistance to tyrosine kinase inhibitors (TKIs) is crucial for developing new lung cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Epidermal growth factor receptor (EGFR) overexpression is common in various cancers, notably in 25% of lung cancer cases.
  • EGFR tyrosine kinase inhibitors (TKIs) are effective treatments targeting specific EGFR mutations.
  • Acquired resistance to first-generation EGFR TKIs necessitates the development of second-generation inhibitors.

Purpose of the Study:

  • To review current molecular targets for non-small-cell lung cancer (NSCLC) therapies.
  • To highlight emerging therapeutic targets for NSCLC based on genomic information.
  • To address the challenge of acquired resistance to EGFR TKIs.

Main Methods:

  • Literature review of current and emerging molecular targets in NSCLC.
  • Analysis of genomic data related to EGFR expression and mutations.
  • Discussion of TKI resistance mechanisms and development of next-generation inhibitors.

Main Results:

  • EGFR mutations are key targets for TKI therapy in NSCLC.
  • Acquired resistance to TKIs is a significant clinical challenge.
  • Genomic profiling is essential for personalized NSCLC treatment strategies.

Conclusions:

  • Continued research into EGFR mutations and resistance mechanisms is vital for improving NSCLC patient outcomes.
  • Development of novel TKIs and combination therapies is ongoing.
  • Genomic information guides the selection of targeted therapies for NSCLC.
Keywords:
EGF receptoracquired resistanceafatinibcetuximabgefitinibneratinibpredictive markerstrastuzumabtyrosine kinase inhibitors

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
577
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
5.1K